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background: The use of adaptive servo-ventilation (ASV) in patients with chronic heart failure (CHF) and Cheyne-Stokes respiration (CSR) improves 
cardiac function and physical capacity. However, the effect of ASV on mortality and admission rates remains unknown. Thus, the aim of this study was 
to investigate whether ASV therapy reduces mortality and risk of admission in CHF patients with CSR.
Methods: We included 75 CHF patients on optimal medication and CSR >25% of sleeping time, in New York Heart Association (NYHA) class ≥III 
and/or left ventricular ejection fraction (LVEF) ≤ 40%. All patients were followed for 18 months from screening or start of ASV treatment in the 
control and ASV group, respectively. Mortality was the primary, while the combination of death or readmission constituted the secondary, outcome 
measure.
results: The ASV group consisted of 31 patients (3 women), including 30 (97%) patients in NYHA ≥III, aged 71±1 years, with LVEF 31±2, and CSR% 
67 (56-82). In the control group, 44 patients (5 women), including 38 (86%) in NYHA ≥III, aged 70±2 years, with LVEF 28±1, and CSR% 49 (34-81), 
were included. At baseline there were no significant differences in age, NYHA class or LVEF between the groups, while CSR% was higher among ASV 
patients (p=0.05). In the control group, 11 (25%) deaths occurred, and 35 (80%) patients reached the combined end-point of death or readmission, 
during the follow-up period. The risk of both time-points was reduced in the ASV group, where 2 (6%) patients died (log rank p=0.03, HR 0.22 
(0.05-1.00)) and 14 (45 %) patients reached the secondary combined end-point (log rank p=0.01, HR 0.42 (0.23-0.79). The improved prognosis 
associated with ASV treatment remained significant even after adjusting for NYHA class, LVEF, CHF medication, and CSR% in a Cox multivariate 
regression model.
conclusion: In CHF patients with CSR, ASV therapy reduced the risk for mortality and hospital readmission rate during 18 months follow up.
